 |
| Modules | |
| Google | |
|
These ads help pay for the upkeep of our site. They are automatically served by Google and are not affiliated with This is MS. | |
| Languages | |
|
Select Interface Language:
| |
| Who's Online | |
There are currently, 70 guest(s) and 16 member(s) that are online.
You are Anonymous user. You can register for free by clicking here | |
| Next Step | |
| Donations | |
|
To remain unbiased, This is MS does not accept corporate sponsorships. Therefore, we must rely on our users to help support us. Please donate to our upkeep if you have the means. Thank you! | |
| |
 | Rumors: Let the wars begin: Rebif versus Tysabri |
As expected, the rivalry between the giant pharmaceutical companies producing MS drugs is starting to truly heat up with the recent introduction of Tysabri.
The article below quotes Serono, maker of the competing treatment Rebif, as saying that Elan/Biogen's newly released Tysabri is off to a slow start-- "It's very early days, but it doesn't look like they're selling much... We know from our experience with Rebif that the US is a slow market, very difficult to penetrate." (This is MS community: Is this true? If you're on Tysabri, please post in our Tysabri user's thread)
This kind of rivalry is no surprise, as the stock price of Serono has taken a large hit over recent months, purportedly because of worries that Tysabri will steal market share from Rebif.
More interesting than this predictable tit-for-tat argument is that Serono commented on Mylinax, oral cladribine (article below). Serono said,: "It all depends on how quickly we can recruit patients for the trial, but we anticipate finishing trials by 2007, which means it could be on the market by 2008, 2009 latest..."
"We believe from our market research that this (an oral MS treatment) is the holy grail," he said, deeming the drug a potential blockbuster.
Advertisement
Source
The source article can be found here:
http://yahoo.reuters.com/financeQuoteCompanyNewsArticle.jhtml?duid=
mtfh09488_2005-01-14_14-22-46_l14635521_newsml
|
|
|
|
| |
| Login | |
|
Don't have an account yet? You can create one. As a registered user you have some advantages like theme manager, comments configuration and post comments with your name. | |
| Related Links | |
| Article Rating | |
Average Score: 5
Votes: 1
| |
| Options | |
|
Associated Topics
 |
|
Re: Let the wars begin: Rebif versus Tysabri (Score: 1)
by AmazingGrace on Monday, June 06 @ 14:58:12 CDT
(User Info | Send a Message) | Why should Tysabri (Antegren) pose a threat to Rebif? Antegren was developed by Elan and hijacked by Biogen to rescue Avonex after studies revealed the ineffectiveness of Avonex as compared to Rebif. Trials of Antegren have been conducted in combination with Avonex, misleading the public about the efficacy of Avonex. With Antegren to boost the results, no one bothered to question the effectivenes of Avonex. What was a headline issue the year before, was completely forgotten.
As soon as I can get my hands on Antegren I plan to take it in conjuction with Rebif, not Avonex. Why would I suddenly switch to the ineffective interferon, just because Biogen/Elan have become strange bedfellows? I might have a few lesions, but I'm not that brain damaged! Rebif has healed all of my original lesions, some as large as 10 mm and has continued to heal the few tiny lesions as they develop. With Antegren to re-establish the BBB, and Rebif to heal the old damage, the prognosis is very good. |
|
|
|
|
